Cargando…
Predicting Outcomes in Patients With Diffuse Large B-Cell Lymphoma Treated With Standard of Care
In diffuse large B-cell lymphoma (DLBCL), predictive modeling may contribute to targeted drug development by enrichment of the study populations enrolled in clinical trials of DLBCL investigational drugs to include patients with lower likelihood of responding to standard of care. In clinical practic...
Autores principales: | Galaznik, Aaron, Reich, Christian, Klebanov, Greg, Khoma, Yuriy, Allakhverdiiev, Eldar, Hather, Greg, Shou, Yaping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421613/ https://www.ncbi.nlm.nih.gov/pubmed/30906191 http://dx.doi.org/10.1177/1176935119835538 |
Ejemplares similares
-
Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Ling, et al.
Publicado: (2019) -
Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
por: Galaznik, Aaron, et al.
Publicado: (2018) -
How I treat diffuse large B-cell lymphoma
por: Melchardt, T., et al.
Publicado: (2023) -
Primary bladder lymphoma, diffuse large B-cell type: Case report and literature review of 26 cases
por: Simpson, W. Greg, et al.
Publicado: (2015) -
An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022)